These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 23583215)

  • 1. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
    Roque DM; Bellone S; English DP; Buza N; Cocco E; Gasparrini S; Bortolomai I; Ratner E; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Santin AD
    Cancer; 2013 Jul; 119(14):2582-92. PubMed ID: 23585021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel.
    Roque DM; Buza N; Glasgow M; Bellone S; Bortolomai I; Gasparrini S; Cocco E; Ratner E; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Santin AD
    Clin Exp Metastasis; 2014 Jan; 31(1):101-10. PubMed ID: 24005572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro.
    Paik D; Cocco E; Bellone S; Casagrande F; Bellone M; Siegel EE; Richter CE; Schwartz PE; Rutherford TJ; Santin AD
    Gynecol Oncol; 2010 Oct; 119(1):140-5. PubMed ID: 20673976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
    Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J
    Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
    Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
    Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression.
    Carrara L; Guzzo F; Roque DM; Bellone S; Emiliano C; Sartori E; Pecorelli S; Schwartz PE; Rutherford TJ; Santin AD
    Gynecol Oncol; 2012 Apr; 125(1):231-6. PubMed ID: 22209775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary.
    Choi CH; Sung CO; Kim HJ; Lee YY; Song SY; Song T; Kim J; Kim TJ; Lee JW; Bae DS; Kim BG
    Hum Pathol; 2013 Jun; 44(6):1017-23. PubMed ID: 23290009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents?
    English DP; Roque DM; Santin AD
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):63-74. PubMed ID: 23259428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
    Mozzetti S; Ferlini C; Concolino P; Filippetti F; Raspaglio G; Prislei S; Gallo D; Martinelli E; Ranelletti FO; Ferrandina G; Scambia G
    Clin Cancer Res; 2005 Jan; 11(1):298-305. PubMed ID: 15671559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
    Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
    Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study.
    Mok TS; Choi E; Yau D; Johri A; Yeo W; Chan AT; Wong C
    Oncology; 2006; 71(3-4):292-6. PubMed ID: 17657173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms of patupilone resistance.
    Mozzetti S; Iantomasi R; De Maria I; Prislei S; Mariani M; Camperchioli A; Bartollino S; Gallo D; Scambia G; Ferlini C
    Cancer Res; 2008 Dec; 68(24):10197-204. PubMed ID: 19074887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer.
    Du J; Li B; Fang Y; Liu Y; Wang Y; Li J; Zhou W; Wang X
    BMC Cancer; 2015 Jul; 15():536. PubMed ID: 26198101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.
    Hofstetter B; Vuong V; Broggini-Tenzer A; Bodis S; Ciernik IF; Fabbro D; Wartmann M; Folkers G; Pruschy M
    Clin Cancer Res; 2005 Feb; 11(4):1588-96. PubMed ID: 15746064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
    Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
    Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
    Cai P; Lu P; Sharom FJ; Fang WS
    Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.